Recombinant Mouse ALPL Protein, C-Fc (MY127011) expressed in Mammalian Cells, spanning Phe18-Ser502. Purity: >90% by SDS-PAGE.
Highlights
●Fc Fusion — Enhanced stability with Protein A/G purification compatibility.
●Mammalian Expression — Proper folding and native glycosylation.
●High Purity — >90% purity verified by SDS-PAGE.
Expression system
Mammalian cells
Accession
P09242
Protein length
Phe18-Ser502
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Species
Mus musculus (Mouse)
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Predicted molecular weight
81.91 kDa
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol.
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alkaline phosphatase, tissue-nonspecific isozyme is a ~57 kDa protein. Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis. Has broad substrate specificity and can hydrolyze a considerable variety of compounds: however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural substrates. Plays an essential role in skeletal and dental mineralization via its ability to hydrolyze extracellular diphosphate, a potent mineralization inhibitor, to phosphate: it thereby promotes hydroxyapatite crystal formation and increases inorganic phosphate concentration. Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix. Also promotes dephosphorylation of osteopontin (SSP1), an inhibitor of hydroxyapatite crystallization in its phosphorylated state; it is however unclear whether ALPL/TNAP mediates SSP1 dephosphorylation via a direct or indirect manner.
1. Fedde, KN. et al. (1999) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 14, 2015-26. PMID: 10620060
2. Wennberg, C. et al. (2000) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 15, 1879-88. PMID: 11028439
3. Anderson, HC. et al. (2004) The American journal of pathology 164, 841-7. PMID: 14982838
4. Simão, AM. et al. (2013) Calcified tissue international 93, 222-32. PMID: 23942722
5. Sun, Y. et al. (2021) Nature 593, 580-585. PMID: 33981039
6. Ciancaglini, P. et al. (2010) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25, 716-23. PMID: 19874193
7. Johnson, KA. et al. (2000) American journal of physiology. Regulatory, integrative and comparative physiology 279, R1365-77. PMID: 11004006
8. Hessle, L. et al. (2002) Proceedings of the National Academy of Sciences of the United States of America 99, 9445-9. PMID: 12082181
中文
English
한국어
日本語
Español
Français
Русский
